Randomized Double Blinded Placebo-controlled Trial of the Once Daily 5mg Dose of Solifenacin Succinate vs. Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 08 Dec 2016
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 05 Dec 2016 Planned End Date changed from 1 Nov 2009 to 1 Apr 2009.
- 20 Nov 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 09 Nov 2008 New trial record.